Skip to main content

Table 1 Patients’ characteristics and pre-AA history

From: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

Population (N = 306)
   Median [range]
Age   63 [46–82]
  N (%)
Initial Gleason score   
4 - 6 33 (10.8%)
7 92 (30.0%)
8 - 10 134 (43.8%)
missing 47 (15.4%)
Sites of metastasis before CT   
Bone only 144 (47.1%)
Visceral only 57 (18.6%)
Multiple 105 (34.3%)
Bone 246 (80.4%)
Nodes 133 (43.5%)
Lung 22 (7.2%)
Liver 17 (5.6%)
Brain 1 (0.3%)
Other 13 (4.3%)
Sites of metastasis before AA   
Bone only 127 (41.5%)
Visceral only 30 (9.8%)
Multiple 149 (48.7%)
Bone 275 (89.9%)
Nodes 146 (47.7%)
Lung 34 (11.1%)
Liver 26 (8.5%)
Brain 5 (1.6%)
Other 18 (5.9%)
PSA before CT (ng/mL) Median [range] Missing
  45.4 [0–4967] 37 (12.1%)
PSA before AA (ng/mL) Median [range]  
  121.2 [0.15 - 8322] 13 (4.2%)
Hormone treatment duration (months) Median [range]  
  31.6 [0–201]  
CT treatment duration if one line (months) Median [range  
  4.9 [0.3-20.7]  
CT treatment duration if more than 1 line (months) Median [95% CI]  
  6.2 [0 – 50.2]  
Lines of CT before AA Median [range]  
  1 [1-5]  
Number of lines of CT before AA N %
1 170 55.6
2 103 33.7
3 20 6.5
4 10 3.3
5 3 1.0
Number of lines of CT after AA N %
0 139 45.4
1 79 25.8
2 52 17
3 29 9.5
4 7 2.3
First line CT after AA (if applicable) N %
Cabazitaxel 51 30.6
Docetaxel rechallenge 44 26.4
Distilbene 17 10.2
Mitoxantrone 14 8.5
Enzalutamide 13 7.7
Other 28 16.6